title: Basic fibroblast growth factor modulates corneal wound healing after excimer laser keratomileusis in rabbits.
abstract: We have previously demonstrated beneficial effects of basic fibroblast growth factor (bFGF) on corneal epithelial healing in different in vivo models. In the present study, we investigated the influence on epithelial and stromal healing of topical bFGF after excimer laser keratomileusis in a rabbit model. The corneas of 24 New Zealand white rabbits were deepithelialized (7-mm diameter) and subsequently received identical deep stromal laser ablations (depth, 50 microns; 6 D; diameter, 5 mm). The animals were randomly assigned to one of four treatment groups: PBS (control); bFGF at 500 ng/application; dexamethasone 0.1%, and bFGF+dexamethasone (n = 12 eyes/group). All treatments were given four times daily; with bFGF being given until complete epithelial healing and dexamethasone and PBS, until 3 months postsurgery. Wound surface regression on time was determined by means of computer-assisted image analysis of fluorescein-stained corneas. Corneal opacity was scored using slit-lamp observation and graded following a previously established scoring system. As compared with the other three treatment groups, a highly significant acceleration in the rate of epithelial wound healing was found after bFGF application for 2-3 days only (P < 0.001). A combined therapy (bFGF+steroid) had no effect on the healing rate. As compared with control values, the peak scores for subepithelial haze were significantly lower in eyes that had received bFGF; the regression on time of the haze in the growth factor group paralleled that in eyes receiving continuous steroid treatment. These results demonstrate for the first time the efficiency of a growth factor in modulating the wound-healing response after excimer laser photoablation.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Ophthalmology, Hôtel-Dieu Hospital, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Rieck
authors.forename: T
authors.initials: T
authors.lastname: David
authors.forename: C
authors.initials: C
authors.lastname: Hartmann
authors.forename: G
authors.initials: G
authors.lastname: Renard
authors.forename: Y
authors.initials: Y
authors.lastname: Courtois
authors.forename: Y
authors.initials: Y
authors.lastname: Pouliquen
mesh_terms: D000818:Animals; D003315:Cornea / Q000502:physiology* / Q000601:surgery; D003318:Corneal Opacity / Q000188:drug therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000494:pharmacology*; D053685:Laser Therapy; D008297:Male; D009883:Ophthalmic Solutions; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D009883:Ophthalmic Solutions; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D003907:Dexamethasone